{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:53Z","timestamp":1783636073670,"version":"3.55.0"},"reference-count":40,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024,10,28]]},"DOI":"10.3960\/jslrt.24061","type":"journal-article","created":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T22:10:33Z","timestamp":1730067033000},"page":"297-306","source":"Crossref","is-referenced-by-count":4,"title":["Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease"],"prefix":"10.3960","volume":"64","author":[{"given":"Asami","family":"Nishikori","sequence":"first","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori Filiz","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Chijimatsu","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himawari","family":"Ueta","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Haratake","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan,"},{"name":"Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine, Isehara, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Fajgenbaum DC, Uldrick TS, Bagg A <i>et al.<\/i> International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017; 129: 1646-1657.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nishimura MF, Nishimura Y, Nishikori A, Yoshino T, Sato Y. Historical and pathological overview of Castleman disease. J Clin Exp Hematop. 2022; 62: 60-72.","DOI":"10.3960\/jslrt.21036"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Iwaki N, Fajgenbaum DC, Nabel CS <i>et al.<\/i> Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016; 91: 220-226.","DOI":"10.1002\/ajh.24242"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Nishimura Y, Fajgenbaum DC, Pierson SK <i>et al.<\/i> Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96: 1241-1252.","DOI":"10.1002\/ajh.26292"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nishimura Y, Nishimura MF, Sato Y. International definition of iMCD-TAFRO: future perspectives. J Clin Exp Hematop. 2022; 62: 73-78.","DOI":"10.3960\/jslrt.21037"},{"key":"6","unstructured":"6 Mori S, Mohri N. [Clinicopathological analysis of systemic nodal plasmacytosis with severe polyclonal hyperimmunoglobulinemia]. Proceedings of the Japanese Society of Pathology. 1978; 67: 252-253."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Takeuchi K. Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980. J Clin Exp Hematop. 2022; 62: 79-84.","DOI":"10.3960\/jslrt.22011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Nishikori A, Nishimura MF, Nishimura Y <i>et al.<\/i> Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Int J Mol Sci. 2022; 23: 10301.","DOI":"10.3390\/ijms231810301"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Zhang L, Dong YJ, Peng HL <i>et al.<\/i> A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. Lancet Reg Health West Pac. 2023; 34: 100720.","DOI":"10.1016\/j.lanwpc.2023.100720"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Nishikori A, Nishimura MF, Fajgenbaum DC, <i>et al.<\/i> Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. J Clin Pathol. 2024. Feb 20: jcp-2023-209280. doi: . Online ahead of print.","DOI":"10.1136\/jcp-2023-209280"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020; 383: 2255-2273.","DOI":"10.1056\/NEJMra2026131"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nishikori A, Nishimura MF, Nishimura Y <i>et al.<\/i> Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease. Pathol Int. 2022; 72: 43-52.","DOI":"10.1111\/pin.13185"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018; 132: 2323-2330.","DOI":"10.1182\/blood-2018-05-848671"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Abe N, Kono M, Kono M <i>et al.<\/i> Glycogen synthase kinase 3\u03b2\/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. Br J Haematol. 2022; 196: 1194-1204.","DOI":"10.1111\/bjh.17993"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Arrizabalaga L, Risson A, Ezcurra-Hualde M, Aranda F, Berraondo P. Unveiling the multifaceted antitumor effects of interleukin 33. Front Immunol. 2024; 15: 1425282.","DOI":"10.3389\/fimmu.2024.1425282"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Sumiyoshi R, Koga T, Kawakami A. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease\/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome. Biomedicines. 2024; 12: 1141.","DOI":"10.3390\/biomedicines12061141"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Iwaki N, Gion Y, Kondo E <i>et al.<\/i> Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017; 7: 42316.","DOI":"10.1038\/srep42316"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 van Rhee F, Wong RS, Munshi N <i>et al.<\/i> Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014; 15: 966-974.","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kanda J, Kawabata H, Yamaji Y <i>et al.<\/i> Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol. 2007; 85: 207-211.","DOI":"10.1532\/IJH97.06186"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Pierson SK, Shenoy S, Oromendia AB <i>et al.<\/i> Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021; 5: 3445-3456.","DOI":"10.1182\/bloodadvances.2020004016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Fajgenbaum DC, Langan RA, Japp AS <i>et al.<\/i> Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019; 129: 4451-4463.","DOI":"10.1172\/JCI126091"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010; 86: 211-218.","DOI":"10.1093\/cvr\/cvq076"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022; 12: 1023177.","DOI":"10.3389\/fonc.2022.1023177"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Xue C, Yao Q, Gu X <i>et al.<\/i> Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023; 8: 204.","DOI":"10.1038\/s41392-023-01468-7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Vignais ML, Gilman M. Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system. Mol Cell Biol. 1999; 19: 3727-3735.","DOI":"10.1128\/MCB.19.5.3727"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012; 4: a011254.","DOI":"10.1101\/cshperspect.a011254"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011; 75: 50-83.","DOI":"10.1128\/MMBR.00031-10"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Phillips AD, Kakkis JJ, Tsao PY, Pierson SK, Fajgenbaum DC. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. J Cell Mol Med. 2022; 26: 3147-3152.","DOI":"10.1111\/jcmm.17251"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Arenas DJ, Floess K, Kobrin D <i>et al.<\/i> Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020; 135: 1673-1684.","DOI":"10.1182\/blood.2019002792"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Dhall A, Patiyal S, Sharma N, Devi NL, Raghava GPS. Computer-aided prediction of inhibitors against STAT3 for managing COVID-19 associated cytokine storm. Comput Biol Med. 2021; 137: 104780.","DOI":"10.1016\/j.compbiomed.2021.104780"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Gajjela BK, Zhou MM. Calming the cytokine storm of COVID-19 through inhibition of JAK2\/STAT3 signaling. Drug Discov Today. 2022; 27: 390-400.","DOI":"10.1016\/j.drudis.2021.10.016"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Salem F, Li XZ, Hindi J <i>et al.<\/i> Activation of STAT3 signaling pathway in the kidney of COVID-19 patients. J Nephrol. 2022; 35: 735-743.","DOI":"10.1007\/s40620-021-01173-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Lee DW, Santomasso BD, Locke FL <i>et al.<\/i> ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Luo C, Ruan Y, Sun P <i>et al.<\/i> The Role of Transcription Factors in Coronary Artery Disease and Myocardial Infarction. Front Biosci (Landmark Ed). 2022; 27: 329.","DOI":"10.31083\/j.fbl2712329"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Zhou H, Geng F, Chen Y <i>et al.<\/i> The mineral dust-induced gene, mdig, regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma by modulating the expression of VEGF-A\/C\/D via EGFR and HIF-1\u03b1 signaling. Oncol Rep. 2021; 45: 60.","DOI":"10.3892\/or.2021.8011"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol. 2011; 55: 383-388.","DOI":"10.1387\/ijdb.103216dr"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014; 31: 31-37.","DOI":"10.1016\/j.coi.2014.09.004"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Antonelli A, Ferrari SM, Giuggioli D <i>et al.<\/i> Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014; 13: 272-280.","DOI":"10.1016\/j.autrev.2013.10.010"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Liu M, Guo S, Hibbert JM <i>et al.<\/i> CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011; 22: 121-130.","DOI":"10.1016\/j.cytogfr.2011.06.001"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Nishimura Y, Nishikori A, Sawada H <i>et al.<\/i> Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease? J Clin Exp Hematop. 2022; 62: 99-105.","DOI":"10.3960\/jslrt.21038"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/4\/64_24061\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T05:04:30Z","timestamp":1735362270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/4\/64_24061\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24061","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"24061"}}